- Home
- TRC vs FULC Comparison
TRC vs FULC Comparison
Compare TRC & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRC
- FULC
- Stock Information
- Founded
- TRC 1843
- FULC 2015
- Country
- TRC United States
- FULC United States
- Employees
- TRC N/A
- FULC N/A
- Industry
- TRC Real Estate
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- TRC Finance
- FULC Health Care
- Exchange
- TRC Nasdaq
- FULC Nasdaq
- Market Cap
- TRC 432.5M
- FULC 468.1M
- IPO Year
- TRC N/A
- FULC 2019
- Fundamental
- Price
- TRC $16.26
- FULC $11.57
- Analyst Decision
- TRC
- FULC Strong Buy
- Analyst Count
- TRC 0
- FULC 7
- Target Price
- TRC N/A
- FULC $12.71
- AVG Volume (30 Days)
- TRC 95.3K
- FULC 926.2K
- Earning Date
- TRC 11-06-2025
- FULC 10-29-2025
- Dividend Yield
- TRC N/A
- FULC N/A
- EPS Growth
- TRC N/A
- FULC N/A
- EPS
- TRC 0.11
- FULC N/A
- Revenue
- TRC $46,420,000.00
- FULC N/A
- Revenue This Year
- TRC N/A
- FULC N/A
- Revenue Next Year
- TRC N/A
- FULC N/A
- P/E Ratio
- TRC $143.52
- FULC N/A
- Revenue Growth
- TRC 15.71
- FULC 2752.05
- 52 Week Low
- TRC $14.71
- FULC $2.32
- 52 Week High
- TRC $19.39
- FULC $12.19
- Technical
- Relative Strength Index (RSI)
- TRC 51.96
- FULC 68.33
- Support Level
- TRC $15.54
- FULC $10.75
- Resistance Level
- TRC $16.17
- FULC $12.05
- Average True Range (ATR)
- TRC 0.40
- FULC 0.76
- MACD
- TRC 0.00
- FULC 0.35
- Stochastic Oscillator
- TRC 59.30
- FULC 87.20
About TRC Tejon Ranch Co
Tejon Ranch Co is a diversified real estate development and agribusiness company committed to responsibly using its land and resources to meet the housing, employment, and lifestyle needs of Californians and create value for its shareholders. It has five segments namely Real Estate - Commercial/Industrial, Real Estate - Resort/Residential, Mineral Resources, Farming, and Ranch Operations.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.